Search

PX-478

PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. … PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

Pucotenlimab

It received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.

Nirogacestat

Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase

APD668

APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

1D09C3

1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC

Allosamidin

Allosamidin exhibits extremely potent inhibitory activity against chitinases from a number of sources, particularly from Candida albicans, and can be utilized as potent antifungal agent.

Isoluminol

Acrylic Acid

A α,β-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.

Bufogenin

Bufogenin is a small molecule drug. Bufogenin has a monoisotopic molecular weight of 384.23 Da.

Rilapladib

Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.